Hutchmed (China) Limited Vesting of awards under the LTIP (9839R)
06 Mars 2023 - 9:30AM
UK Regulatory
TIDMHCM
RNS Number : 9839R
Hutchmed (China) Limited
06 March 2023
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Monday, March 6,
2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM;
SEHK:13) announces that following the announcement of the 2022
annual results of HUTCHMED on February 28, 2023, the following
awards granted under the Long Term Incentive Plan ("LTIP") on April
20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March
3, 2023:-
Number of American
depositary shares
Award Holders ("ADS")
Person Discharging Managerial Responsibilities
Dr Weiguo Su (Executive Director, Chief Executive
Officer and Chief Scientific Officer) 50,431
Mr Johnny Cheng (Executive Director and Chief Financial
Officer) 22,953
Total 73,384
===================
The notification s set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
(a) Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
------------------------------------------------------- -----------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director, Chief Executive Officer and
Chief Scientific Officer
------------------------------------------------------- -----------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
------------------------------------------------------- -----------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing five Ordinary Shares of
instrument US$0.10
Identification code
ADS ISIN: US44842L1035
------------------------------------------------------- -----------------------------------------------------
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under
HUTCHMED's LTIP
------------------------------------------------------- -----------------------------------------------------
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 50,431 ADS
-----------
------------------------------------------------------- -----------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -----------------------------------------------------
e) Date of the transaction 2023-03-03
------------------------------------------------------- -----------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -----------------------------------------------------
(b) Mr Johnny Cheng
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Johnny Cheng
------------------------------------------------------- -----------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Financial Officer
------------------------------------------------------- -----------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
------------------------------------------------------- -----------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing five Ordinary Shares of
instrument US$0.10
Identification code
ADS ISIN: US44842L1035
------------------------------------------------------- -----------------------------------------------------
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under
HUTCHMED's LTIP
------------------------------------------------------- -----------------------------------------------------
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 22,953 ADS
-----------
------------------------------------------------------- -----------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -----------------------------------------------------
e) Date of the transaction 2023-03-03
------------------------------------------------------- -----------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -----------------------------------------------------
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has about 5,000 personnel across all its
companies, at the center of which is a team of about 1,800 in
oncology/immunology. Since inception HUTCHMED has been focused on
bringing cancer drug candidates from in-house discovery to patients
around the world, with its first three oncology drugs now approved
and marketed in China. For more information, please visit:
www.hutch--med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 306 4490
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@soleburystrat.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055
(Mobile) HUTCHMED@fticonsulting.com
Asia - Zhou Yi, Brunswick +852 97 83 6894 (Mobile)
HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHJFMRTMTIMMBJ
(END) Dow Jones Newswires
March 06, 2023 03:30 ET (08:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
